Feeling cold on tirzepatide is something people report during weight loss, but it isn't a listed common side effect of Zepbound. Eating less and losing insulating fat are possible explanations. Persistent coldness can also have another cause, including an underactive thyroid or anemia.
The first chilly mornings of October can make the change more noticeable. Needing another layer is one thing; shaking with sweating, confusion, or fever is another. The pattern matters more than the fact that treatment started recently.
What the current labels say about feeling cold on tirzepatide
As of October 1, 2026, the day this article was written, the Zepbound prescribing information carries “Revised: 08/2026.” Neither “feeling cold” nor “chills” appears in its adverse-reaction tables or postmarketing section, which lists reactions reported after the medicine reached the market.
The Wegovy prescribing information, marked “Revised: 6/2026,” doesn't list those terms in those sections either. Wegovy contains semaglutide, a different weight-management medicine.
That leaves an important distinction: a symptom can be real without having a measured frequency or a proven drug-related cause. The labels don't provide a percentage for feeling cold. They also don't establish that every new chill comes from treatment.
Why eating less can change how warm someone feels
A smaller appetite can mean a substantial change in food intake. In a 28-week study by Heise and colleagues, published in Diabetes Care in 2023, tirzepatide reduced appetite and food intake compared with placebo, a treatment without the active medicine. The study involved adults with type 2 diabetes. It didn't establish the cause of cold sensations.
Separate human studies help explain why food intake belongs in the conversation. Adaptive thermogenesis means the body uses less energy than expected after weight loss.
In the CALERIE trial analysis, Redman and colleagues studied 53 adults without obesity for two years, in Cell Metabolism in 2018. Those restricting calories used about 80–120 fewer calories daily than expected from their weight changes. That was a measured energy-saving response, not a tirzepatide finding.
Less insulation, and the first cold mornings
A 2011 study by Soare and colleagues in Aging compared three groups of 24 people. Those practicing long-term calorie restriction had an average internal temperature about 0.2°C lower than the comparison groups. Lean endurance runners didn't show the same reduction.
These findings make reduced intake a plausible contributor. They don't prove that tirzepatide lowers body temperature, or that eating very little is harmless. A provider can review whether the smaller meals still meet nutritional needs.
Lower intake isn't the only possible change. Body fat helps hold warmth. MedlinePlus's clinical overview of cold intolerance notes that people with very little body fat may tolerate cold poorly. Cold intolerance means unusual sensitivity to cold temperatures.
After weight loss, the same coat or room temperature may feel different. Less insulation is a possible contributor, rather than a complete explanation for every symptom.
Layers and dry clothing are ordinary ways to stay comfortable outdoors. A warm room and a regular meal pattern also make useful context for a symptom discussion. Coldness that continues indoors, worsens, or seems extreme deserves a clinical review.
There is no established timeline saying this must disappear after a certain number of injections. A note of when it happens—after a missed meal, outdoors, or throughout the day—gives the provider more to work with.
What a clinician may want to rule out
MedlinePlus lists an underactive thyroid and anemia among possible causes of cold intolerance. Anemia means too few healthy red blood cells to carry enough oxygen. The review may include thyroid tests and a blood count, depending on the history.
Existing thyroid treatment belongs in that conversation. Our tirzepatide and thyroid guide covers why thyroid prescriptions sometimes need review during weight changes.
Sudden coldness with sweating, shakiness, or confusion raises a different question: low blood sugar, also called hypoglycemia. Zepbound's label warns that the risk increases with insulin or sulfonylureas, diabetes pills that prompt insulin release. The tirzepatide and low-blood-sugar guide explains those combinations.
When chills need a different kind of attention
Coldness accompanied by tirzepatide-related tiredness also deserves context, rather than an assumption about its cause. Fever, cough, and body aches belong in an illness review; the flu-season guide covers that separate question.
Confusion or slurred speech after cold exposure needs urgent assessment. A temperature below 95°F (35°C) is an emergency, according to CDC's hypothermia guidance. Hypothermia means abnormally low body temperature.
Cold-weather travel: refrigerated doesn't mean frozen
A chilly car or luggage compartment is not a controlled refrigerator. Zepbound's label specifies 36°F–46°F (2°C–8°C) for refrigerated storage of its pens and vials.
Its wording is direct: “Do not freeze ZEPBOUND. Do not use ZEPBOUND if frozen.” Thawing doesn't undo that instruction.
The time allowed outside refrigeration depends on the presentation:
| Zepbound presentation | Label limit outside refrigeration |
|---|---|
| Single-dose pen or vial | Up to 21 total days at no more than 86°F (30°C) |
| Unopened multi-dose vial or KwikPen | Discard after 30 days at room temperature, no more than 86°F (30°C) |
| Opened multi-dose vial or KwikPen | Discard after 30 total days at room temperature, 30 days after first use, or four weekly doses |
Those are brand-label facts. A compounded prescription follows its dispensing pharmacy's storage directions and use-by date. A pharmacist can assess suspected freezing or an uncertain travel exposure before another injection is considered.
Semaglutide has its own storage rules
Semaglutide isn't an established way to avoid feeling cold. The Wegovy label also lacks a measured rate for that symptom.
Its single-dose pens are refrigerated at 36°F–46°F (2°C–8°C). Before cap removal, the label allows up to 28 days at 46°F–86°F (8°C–30°C). It also excludes use after freezing and cautions against storage directly beside the refrigerator's cooling element. Other presentations have different limits.
A switch is a prescribing decision, with the symptom history and other medicines considered together. Storage rules don't transfer automatically between products.
What recent cold-exposure research actually adds
As of October 1, 2026, the day this article was written, a mouse study published online September 10, 2026, in the American Journal of Physiology found no additional weight loss from combining intermittent cold exposure with tirzepatide. It tested cold exposure as a way to increase energy use. It didn't study people feeling cold during treatment or establish a reason to seek cold exposure.
Through Promise, tirzepatide and semaglutide are dispensed as compounded medications, which are different from an FDA-approved product: the formulations offered here are not FDA-approved. FDA explains that compounded drugs do not undergo its premarket review for safety, effectiveness, or quality.
A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. At Promise, a licensed U.S. provider reviews every request, and not everyone qualifies.
